Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.

Kevin M Tuffy,Bahar Ahani,Anastasia A Aksyuk,Miles Avila,Tyler Brady,Gustavo H Kijak,Gavin Koh,Myron J Levin,Tiffany L Roe,Nicolette Schuko, Jesse Thissen,Andrew Ustianowski,Tianhui Zhang,Elizabeth J Kelly,Katie Streicher

The Journal of infectious diseases（2023）

引用 0|浏览6

暂无评分

摘要

Symptomatic COVID-19 breakthrough cases in PROVENT were not due to resistance-associated substitutions in AZD7442 binding sites or lack of AZD7442 exposure.

查看译文

关键词

AZD7442, COVID-19, SARS-CoV-2, cilgavimab, monoclonal antibody, tixagevimab, viral neutralization, viral resistance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要